Although it is known that several cardioprotective interventions lose its effectiveness with aging and prolonged diabetes [9,30] due to impaired cellular signalling, FA treatment was anticipated to be effective because it targeted one of the crucial age– and diabetes-induced impairments (i.e. eNOS dysfunction). This evidence concerns the gene NOS3 and diabetes mellitus.